Thrive Type 1 Blog

The FDA just approved Tzield for children ages 8–17 diagnosed with stage 3 T1D, making it the first drug to slow insulin loss after diagnosis.

At the ADA's 86th Scientific Sessions, researchers announced that all 12 patients in an islet transplant trial using tegoprubart are now off external insulin. Here's what this means — and why ADA 2026 was a watershed moment for T1D.

For the first time, an automated insulin delivery system has been cleared in the US for use during pregnancy with type 1 diabetes. Here's why this matters and what it means for T1D women planning families.

On May 29, the FDA approved Afrezza — an inhaled mealtime insulin — for children and adolescents ages 6 and older. It's the first needle-free mealtime insulin for kids with diabetes. Here's what parents need to know.

New data from England and Wales shows the NHS rollout of hybrid closed-loop systems is reaching patients more equitably than previous diabetes technologies. Here's what that means — and why it matters for the future of T1D care everywhere.

A landmark 10-year German study screened more than 220,000 children for type 1 diabetes. The results show that population-wide screening can catch T1D years before crisis — and DKA rates drop dramatically when families know in advance.

A team at Karolinska Institutet has developed a reliable new method for producing high-quality insulin cells from stem cells — and they reversed diabetes in mice. Here's a plain-language breakdown of what happened and why it matters.

A new clinical trial at UW Medicine is enrolling adults recently diagnosed with type 1 diabetes to test a drug that may protect insulin-producing beta cells. Here's what the research is about and why it matters for newly diagnosed families.

The FDA has expanded approval of Tzield (teplizumab) to children as young as 1 year old. It's the world's first disease-modifying therapy for type 1 diabetes, and it can delay the disease's onset by years. Here's what parents need to know.

Meta Summary: A new gene therapy called KRIYA-839 is entering human trials for type 1 diabetes. It works by turning muscle cells into insulin producers. Here's what the PROGRESS study means for T1D families.

Scientists in Sweden have created lab-grown insulin cells that reversed diabetes in mice. Here's what the research means, why it matters, and what the path to a human treatment might look like.

The world's top T1D researchers just met in Barcelona for ATTD 2026. Here are five breakthroughs that could change how your child manages type 1 diabetes — from GLP-1 therapies to AI-powered glucose models.

A Stanford breakthrough from this week has the T1D research community buzzing - and for good reason. Here's what it means in plain language for families living with T1D right now.

If you've been living with type 1 diabetes for any length of time, you've probably learned to take "breakthrough" headlines with a grain of salt. But the past two weeks? They've delivered the kind of news that genuinely deserves the word. From a major international conference to new cure strategies and game-changing device launches, the T1D world is buzzing — and for all the right reasons.

A new immunosuppressive drug called tegoprubart is showing remarkable early results in islet cell transplant patients with type 1 diabetes — achieving sustained insulin independence with far fewer side effects than traditional anti-rejection medications. Here’s what this could mean for the future of T1D treatment.

If you use a Dexcom G6 or G7, you may be eligible for 12 months of free access to RxFood — but it’s not automatic just because you have a Dexcom account. While RxFood does support logging in with Dexcom credentials, the free year is typically unlocked through a healthcare provider or clinician invitation, particularly in Canada. Here’s how it works and what to watch out for.

Scientists are exploring a bold new way to stop type 1 diabetes at its source by reprogramming the immune system to protect and regenerate the insulin-making cells it normally destroys. Supported by significant funding, this research combines immune engineering and stem cell biology to move beyond symptom management toward true immune tolerance — though it’s still in early stages.

Dexcom is discontinuing the G6 across the U.S., Canada, the UK, Europe, and Australia as the company shifts to the G7. Users should check pharmacy stock, confirm insurance coverage, and prepare for the transition. The G6 will become increasingly difficult to refill as Dexcom phases out manufacturing and distributors shift inventory to the G7.

A father’s journey running seven marathons on seven continents in seven days is inspiring the global Type 1 Diabetes community. Learn how his mission fuels hope, resilience, and purpose for people living with T1D.

If you live with type 1 diabetes, most “breakthrough” headlines can feel distant from your day-to-day reality of boluses, site changes, and alarms. But a piece of news from this past week is worth pausing on - because it’s not just about better management. It’s about changing when type 1 begins for people at high risk.

Living with T1D means managing so much more than just blood sugar—long-term risks like kidney disease are ever-present for many of us. So when a new study comes along showing solid progress, it’s worth sharing. At ThriveWithType1 we believe in keeping hope alive - and today’s news offers just that.

A $3.2 M NIDDK grant to Scripps Research shines fresh light on how Type 1 Diabetes begins, focusing on rare pancreatic cells and potential prevention strategies.

This week, scientists announced that two people with type 1 diabetes no longer need to take insulin after getting a special transplant of insulin-making cells. They also used a new medicine that helps protect those cells without the strong side effects of older drugs.

If you’re living with type 1 diabetes (T1D), you know the daily rhythm: checking blood sugar, doing insulin doses, watching what you eat. It can feel like you never stop being on guard. But some exciting research published on October 8, 2025, by Scripps Research is giving hope — not just for managing T1D, but for changing the way we think about it.

A first-in-human trial using CRISPR-edited pancreatic cells gives new hope for Type 1 diabetes—insulin production without immune rejection.

This heartfelt article shares a mother's personal journey through her son's Type 1 diabetes diagnosis, highlighting early symptoms to watch for and emphasizing that with the right support, technology, and care, children with the condition can thrive.

From delaying the onset of type 1 diabetes with immunotherapy to restoring insulin production with stem cells and easing life through smart delivery systems, a new era of type 1 diabetes treatment is emerging, but only if access and equity keep pace.

The study develops and validates the Diabetes Strengths and Resilience (DSTAR-Child) scale, a brief measure to assess strengths and resilience in children aged 9 to 13 with type 1 diabetes, showing it is reliable and associated with better emotional well-being and glycemic control​​.

Morgan’s story at the Children’s Hospital of Philadelphia showcases a young girl's and her family's empowering journey of advocacy, leading to better diabetes support at her school and inspiring confidence and leadership in managing Type 1 Diabetes.

This Johns Hopkins Bloomberg School of Public Health article details significant improvements in glucose control for people with type 1 diabetes over the past 15 years, driven by the widespread adoption of continuous glucose monitoring and insulin delivery technologies.

Young adults with type 1 diabetes (T1D) often struggle with self-management and achieving target glycemic control, and thus, may benefit from additional support during this challenging developmental life stage. They are also some of the highest users of social media (SM), which may have some benefits to young people with T1D.

Developments from two studies highlighting the potential for machine learning leveraging artificial intelligence (AI) technology to improve early-stage identification of type 1 diabetes were presented as late-breaking poster sessions at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago.

A groundbreaking diabetes treatment at Manning Family Children’s Hospital helped young Ma’Lonniya delay the progression of type 1 diabetes, restoring her energy and happiness while providing hope for her family.

Five inspiring celebrities—including Nick Jonas, Noah Gray, Jean Smart, Sonia Sotomayor, and Este Haim—show that type 1 diabetes can be managed while achieving success in music, sports, entertainment, and public service.

We're thrilled to launch this community platform dedicated to helping people with Type 1 diabetes live their best lives. Discover what exciting features and resources we have planned for you.